Adjust Text Size:change font sizechange font sizechange font sizechange font sizechange font sizechange font size

Access to the latest research — for scientists and people living with PD alike — in PDF's new scientific journal.

Browse Now

Parkinson's HelpLine


Learn More

Science News

Sleep Study - Call for patients


In Chicago, Dr. Cynthia Comella, movement disorder specialist and board-certified sleep neurologist, is interested in trying to abate sleep problems that plague patients with PD. She has received a grant to study the effects of a bedtime dose of the dopamine agonist drug, pergolide (Permax) on treating sleep problems in patients who are taking carbidopa/levodopa (Sinemet).

Patients must not be currently taking pergolide or any other dopamine agonist like bromocriptine (Parlodel), ropinirole (Requip) or pramipexole (Mirapex). The study is double-blind and placebo controlled, which means that some patients will receive pergolide and some will receive a tablet that is not chemically active. Neither the patient nor Dr. Comella and her staff will know whether the patient has been assigned the pergolide or placebo. For all patients, carbodipa/levodopa is continued throughout the study.

As a sleep specialist, Dr. Comella has access to new and innovative recording instruments to assess sleep and PD function. Patients who enroll in the program will be able to use these instruments. Patients do not have to be from the Chicago area, but must be in the position to travel to Rush-Presbyterian St. Luke's Medical Center in Chicago six times during the 12 week study. Whereas travel costs are not covered by the study grant, study medication, access to the assessment equipment, and all laboratory tests are provided to enrolled subjects at no cost.

Patients with sleep problems who would be interested in testing this drug with Dr. Comella should contact the study coordinator Kimberly Janko at 312-563-2900

Source Date: Aug 15 2000